Last $71.70 USD
Change Today +1.54 / 2.19%
Volume 3.3M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:33 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Richard S. Geary Ph.D.

Senior Vice President of Development, Isis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

56$1,785,888
As of Fiscal Year 2014

Background*

Dr. Richard S. Geary, Ph.D has been Senior Vice President of Development at ISIS Pharmaceuticals, Inc. Dr. Geary is responsible for preclinical and clinical development of antisense drugs. From August 2003 to August 2008, Dr. Geary served as Vice President, Preclinical Development at Isis Pharmaceuticals, Inc. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Since joining Isis in 1995, Dr. Geary has been involved ...

Read Full Background

Corporate Headquarters*

2855 Gazelle Court
Carlsbad, California 92010

United States

Phone: 760-931-9200
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BS
Texas A&M University
PhD
The University of Texas System

Other Affiliations*

Annual Compensation*

Salary$411,194
Bonus$224,872
Total Annual Compensation$636,066

Stock Options*

Restricted Stock Awards$357,450
All Other Compensation$16,861
Exercised Options37,200
Exercised Options Value$1,333,433
Exercisable Options22,050
Exercisable Options Value$1,119,871
Unexercisable Options70,731
Unexercisable Options Value$2,254,144
Total Value of Options$4,707,447
Total Number of Options129,981

Total Compensation*

Total Annual Cash Compensation$652,927
Total Short Term Compensation$636,066
Other Long Term Compensation$374,311
Total Calculated Compensation$1,785,888
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $71.65 USD +1.49

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ron Cohen M.D.Founder, Chief Executive Officer, President and Director
Acorda Therapeutics, Inc.
$720.8K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
George Frederick Wilkinson Chief Executive Officer, President and Director
Impax Laboratories Inc.
--
Uli Hacksell Ph.D.Chief Executive Officer, President and Director
ACADIA Pharmaceuticals Inc.
$935.0K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.